Wilk Joshua, Marcus Steven C, West Joyce, Countis Lisa, Hall Rebecca, Regier Darrel A, Olfson Mark
American Psychiatric Institute for Research and Education, Arlington, Virginia, USA.
J Nerv Ment Dis. 2006 Jun;194(6):454-7. doi: 10.1097/01.nmd.0000221289.54911.63.
To compare the clinical characteristics and psychiatric management of antipsychotic nonadherence among outpatients with schizophrenia who either do or do not have current or past comorbid substance use disorders, a national survey was conducted of psychiatrists engaged in the management of schizophrenia. Respondents reported on the presentation and management of one adult patient who had been under their care for at least 1 year and who had been nonadherent with oral antipsychotic medications at some point in the last year. The response rate was 69.3%. Patients with schizophrenia only (N = 190) were compared with patients with schizophrenia and a history of a co-occurring substance use disorder (N = 105). Approximately one third (35.6%) of antipsychotic nonadherent schizophrenia patients had a comorbid substance use disorder. Denial of illness was the most commonly cited primary reason for antipsychotic nonadherence. Psychiatrists were significantly less likely to discuss with comorbid patients than patients without comorbid substance use linkages between antipsychotic adherence and progress toward personal goals (64.5% vs. 78.9%), and significantly less likely to explore the meaning of taking medication to the patient's identity (59.2% vs. 73.3%). However, psychiatrists were approximately two times more likely to add another antipsychotic for patients with substance use disorders (22.8% vs. 11.0%). There were no perceived differences between the two groups in effectiveness of interventions to manage medication nonadherence. Comorbid substance use disorders are common among psychiatric outpatients with schizophrenia who are nonadherent with antipsychotic medications. Some psychological approaches tend to be used less often with patients with comorbid substance use disorders, although when they are used, psychiatrists report they are no less effective than they are for schizophrenia patients without comorbid substance use disorders. These findings suggest that some psychological interventions may tend to be underutilized in the management of medication nonadherence among patients with comorbid schizophrenia and substance use disorders.
为比较患有或未患有当前或既往共病物质使用障碍的精神分裂症门诊患者中抗精神病药物治疗不依从的临床特征及精神科管理情况,对从事精神分裂症管理工作的精神科医生进行了一项全国性调查。受访者报告了一名成年患者的临床表现及管理情况,该患者在其照料下至少1年,且在过去一年中的某个时间点存在口服抗精神病药物治疗不依从的情况。回复率为69.3%。仅患有精神分裂症的患者(N = 190)与患有精神分裂症且有共病物质使用障碍病史的患者(N = 105)进行了比较。约三分之一(35.6%)的抗精神病药物治疗不依从的精神分裂症患者患有共病物质使用障碍。否认患病是抗精神病药物治疗不依从最常被提及的主要原因。与没有共病物质使用障碍的患者相比,精神科医生与共病患者讨论抗精神病药物依从性与个人目标进展之间联系的可能性显著更低(64.5%对78.9%),探索服药对患者身份意义的可能性也显著更低(59.2%对73.3%)。然而,为患有物质使用障碍的患者加用另一种抗精神病药物的精神科医生可能性约为前者的两倍(22.8%对11.0%)。两组在管理药物治疗不依从的干预措施有效性方面没有察觉到差异。共病物质使用障碍在抗精神病药物治疗不依从的精神分裂症门诊患者中很常见。一些心理方法在共病物质使用障碍的患者中使用频率往往较低,不过当使用这些方法时,精神科医生报告它们的效果并不比用于没有共病物质使用障碍的精神分裂症患者时差。这些发现表明,在共病精神分裂症和物质使用障碍患者的药物治疗不依从管理中,一些心理干预措施可能未得到充分利用。